The battle for the "baby-face injection" between two listed companies escalates again.
```
The dispute over the “baby face injection” AestheFill continues to intensify.
Recently, Aimeike (300896.SZ) announced that its subsidiary REGEN Biotech, Inc. (hereinafter referred to as “REGEN”) received a decision from an emergency arbitrator of the Shenzhen International Arbitration Court: REGEN must not independently sell the “polylactic acid facial filler AestheFill” in mainland China before the arbitration award, must not deny the status of Datou Medical Device (Shanghai) Co., Ltd. (hereinafter referred to as “Datou Medical”), a subsidiary of *ST Suwu (600200.SH), as the exclusive distributor in mainland China, and must continue to supply the product to Datou Medical.
In response, Aimeike confirmed to Xin Feng that this decision is a procedural matter regarding the provisional measures applied for by Datou Medical to the arbitration court. According to the "Arbitration Rules," the pre-trial decision is a voluntary provisional resolution, not a final enforceable arbitration result.
On September 15, *ST Suwu also issued a supplementary announcement, admitting, “The actual impact of this emergency arbitrator procedure depends on whether the respondent actually complies, and there is uncertainty over whether it will be implemented.”
This means that REGEN can still independently sell AestheFill in mainland China.
Even so, the dispute between the two parties may have already affected the normal sales of AestheFill.
“AestheFill has been out of stock for two months, and there is no domestic supply. If this continues, neither the new nor old agents will have any goods to sell,” a downstream medical aesthetics institution head told Xin Feng.
In response, Aimeike told Xin Feng: “REGEN shipped to ST Suwu in mid-July this year. Some downstream institutions’ out-of-stock issues may relate to the distributor’s sales strategy.”
Aimeike confirmed to Xin Feng that AestheFill has now been renamed “Zhen’ai Sufe” for sale, and supply has been arranged for cooperating downstream institutions.
Xin Feng searched for the product name “Zhen’ai Sufe” on the Meituan platform and found that currently only two medical aesthetics institutions in Beijing have changed AestheFill’s product name to “Zhen’ai Sufe,” while more institutions are still using the previous Chinese name for AestheFill given by *ST Suwu, “Aisufe.”
Moreover, in Meituan Aesthetics' “Find Brand” function, “Aisufe” is still used as the Chinese name for AestheFill.
Behind the product naming differences, there is also chaos in the pricing system.
Xin Feng noticed that the price of “Aisufe” (200mg) can be as low as 8,700 yuan per vial, while the price of “Zhen’ai Sufe” (200mg) is around 21,000 yuan each.
Whether Aimeike can quickly resume normal subsequent sales of AestheFill and maintain price stability remains to be seen.
Risk Warning and DisclaimerThe market involves risks, and investment needs to be cautious. This article does not constitute personal investment advice, nor does it take into account the unique investment objectives, financial situation, or needs of any individual user. Users should consider whether any opinions, viewpoints, or conclusions in this article are applicable to their specific circumstances. Investments made accordingly are at their own risk. ```